REVIVA PHARMA HLDGS INC
RVPH
RVPH was delisted on the 13th of May, 2026.
48 hedge funds and large institutions have $6.95M invested in REVIVA PHARMA HLDGS INC in 2025 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 11 increasing their positions, 8 reducing their positions, and 12 closing their positions.
50% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 12
38% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 8
14% more funds holding
Funds holding: 42 → 48 (+6)
0.87% less ownership
Funds ownership: 16.6% → 15.73% (-0.87%)
45% less call options, than puts
Call options by funds: $2.25M | Put options by funds: $4.13M
50% less capital invested
Capital invested by funds: $14M → $6.95M (-$7.06M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DP
Diadema Partners
Morristown,
New Jersey
|
+$1.02M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$659K |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$535K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$351K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$340K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$2.47M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.26M |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$931K |
| 4 |
Millennium Management
New York
|
-$425K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$84.1K |
RVPH Hedge Fund Activity: Q1 2025 in Review
48 of the 7,476 institutional investors tracked by Wall St. Rank reported a position in REVIVA PHARMA HLDGS INC (RVPH) for Q1 2025, worth a combined $6.95M — down 50% from $14M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new RVPH positions and 12 closed out — a net gain of 6 holders — while 11 added to existing stakes and 8 trimmed.
The largest buyer was Diadema Partners, opening a new position worth an estimated $1.02M. The largest seller was Armistice Capital, exiting entirely with an estimated $2.47M sold.
- 48 institutional investors held REVIVA PHARMA HLDGS INC (RVPH) as of Q1 2025, up from 42 in Q4 2024.
- Funds reported $6.95M of REVIVA PHARMA HLDGS INC stock for Q1 2025, down 50% quarter-over-quarter.
- 18 funds opened new REVIVA PHARMA HLDGS INC positions in Q1 2025 and 12 closed out, a net change of +6 holders.
- The largest REVIVA PHARMA HLDGS INC buyer in Q1 2025 was Diadema Partners, an estimated $1.02M added.
- The largest REVIVA PHARMA HLDGS INC seller in Q1 2025 was Armistice Capital, an estimated $2.47M sold.
Based on aggregated 13F filings for Q1 2025.